Cue Biopharma (Cue Biopharma) Interest Expense : $-1.40 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cue Biopharma's interest expense for the three months ended in Dec. 2023 was $ -0.51 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.40 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cue Biopharma's Operating Income for the three months ended in Dec. 2023 was $ -13.68 Mil. Cue Biopharma's Interest Expense for the three months ended in Dec. 2023 was $ -0.51 Mil. Cue Biopharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cue Biopharma Interest Expense Historical Data

The historical data trend for Cue Biopharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Interest Expense Chart

Cue Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.71

-1.25

Cue Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.36	-0.37	-0.23	-0.29	-0.51

Cue Biopharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.40 Mil.

Cue Biopharma (NAS:CUE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cue Biopharma's Interest Expense for the three months ended in Dec. 2023 was $-0.51 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-13.68 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $7.36 Mil.

Cue Biopharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Cue Biopharma did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Cue Biopharma (Cue Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

1UC:Germany 1UC:Germany

Address

40 Guest Street, Boston, MA, USA, 02135

Website

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.

Executives

Anish Suri	officer: President and CSO	40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri	director, officer: CEO	40 GUEST STREET, BOSTON MA 02135
Pamela Garzone	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener	director	40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti	officer: Chief Medical Officer	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich	director	40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn	officer: Chief Business Officer	C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar	officer: CFO	40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta	officer: Chief Medical Officer	C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin	officer: SVP, General Counsel and Sec	40 GUEST STREET, BOSTON MA 02135
Tamar D Howson	director
Barry J. Simon	director	2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll	director